Purchase Order 75N91018P00525

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for a GentleMACS Octo Dissociator with heaters (catalog #130-096-427) valued at $20,907.00, awarded August 8, 2018, with completion by September 30, 2018. Performance occurs in Bethesda, Maryland. The order is firm fixed-price with no set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for a GentleMACS Octo Dissociator with heaters valued at $21,688.50 on April 2, 2019. Performance of the firm fixed-price order was completed by June 3, 2019. Work was performed in Auburn, California.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc., valued at $25,881.00, on September 15, 2020, for one GentleMACS Octo Dissociator with heaters. The order carries a firm fixed price and is due for completion by October 15, 2020. Place of performance is Auburn, California. The procurement originated from a solicitation posted August 17, 2020, and due August 24, 2020, with no small business set-aside applied.</p>

The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc., for a GentleMACS Octo Dissociator with heaters, valued at $21,688.50, on August 14, 2019, with completion by September 15, 2019. The equipment will be delivered to Auburn, California. This is a firm fixed-price, non-competitive acquisition reflecting the vendor's position as a specialized sole-source supplier of automated tissue dissociation instruments and related laboratory equipment to the federal research...

The Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI) awarded a $29,858 firm-fixed-price purchase order to Miltenyi Biotec, Inc. to provide one Miltenyi Biotec GentleMACS Octo Dissociator with heating units. The equipment will be used to support the work of the NCI's Center for Immuno-Oncology, Laboratory of Tumor Immunology and Biology. There was no set-aside designation for this procurement, and the contract completion date is July...

<p>The NIH Clinical Center awarded a purchase order to Miltenyi Biotec, Inc. on June 23, 2020, for $24,980.62 to purchase a GentleMACS Octo Dissociator with heaters for dissociating lung tissue samples collected from patient donors into single-cell suspensions. The order carries no set-aside designation and is priced on a firm fixed price basis. Place of performance is Montgomery Village, Maryland. The ultimate completion date is August 26, 2020.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Miltenyi Biotec, Inc. for $21,688.50 on September 5, 2019, to procure a GentleMACS Octo Dissociator with heaters, power cord, and manual. Place of performance is Bethesda, Maryland. The order is firm fixed-price with an ultimate completion date of September 26, 2019.</p>

The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for a GentleMACS Octo Dissociator valued at $27,451.25 on June 24, 2026, with completion by December 31, 2026. No set-aside was used. The award is sole-source under FAR 6.302-1 without competitive procurement. Place of performance is Auburn, California. The dissociator supports the Women's Malignancies Branch in generating viable single-cell suspensions from complex tissues, particularly brain tissue, for molecular...

<p>The NIH Clinical Center issued a purchase order to Miltenyi Biotec, Inc. valued at $24,983.50 for a GentleMACS Octo Dissociator with heaters for perioperative medicine, awarded May 18, 2021, with completion by June 1, 2021. Place of performance is Auburn, California. The order is firm fixed-price with no set-aside applied.</p>

The National Cancer Institute (NCI) has awarded a $31,100 firm-fixed-price purchase order to Miltenyi Biotec, Inc. for the procurement of one Miltenyi Biotec GentleMACS Octo Dissociator with Heating Units. This equipment will be used in support of the Laboratory of Tumor Immunology and Biology (LTIB) at the Center for Immuno-Oncology (CIO) within the NCI's Center for Cancer Research (CCR). The contract has an ultimate completion date of September 30, 2024. Miltenyi Biotec is a global...